Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is common in the general population and associated with increased mortality. Accordingly, physicians commonly encounter patients with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery systolic pressure (PASP) on echocardiography. Although pulmonary arterial vasodilators may often be considered in this setting, these drugs have been predominantly tested in the subset of PH patients with pulmonary arterial hypertension (PAH). Elevated PASP alone is not sufficient for the diagnosis of PAH, and secondary causes of PASP elevation, most commonly left heart disease, are far more prevalent than isolated PAH. Treatment of this more common group of patients with PH due to left heart disease is challenging because there are few evidence-based treatment options, and pulmonary vasodilator therapy may lead to worsening symptoms. Therefore, improving symptoms and avoiding adverse outcomes in patients with PH requires the following: (1) understanding the optimal use of echocardiography for the diagnosis of PH; (2) recognizing the utility and proper interpretation of invasive hemodynamic testing prior to starting pulmonary vasodilator therapy; (3) differentiating PAH from pulmonary venous hypertension due to left heart disease; and (4) understanding the appropriate treatment strategies for PH and resultant right heart failure.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
The initial goal of the algorithm is to determine whether PH is likely present based on echocardiography and whether the PH could be due to a common cause. If PH is present and the cause is not apparent, if symptoms persist despite treatment of the suspected underlying cause, if pulmonary arterial hypertension is suspected, or if treatment with pulmonary vasodilators is being considered, further evaluation is necessary. At this point, additional testing to determine the etiology of PH, evaluation of functional capacity, and invasive hemodynamic testing are all indicated—with the ultimate goals of confirming the PH diagnosis, differentiating pulmonary arterial from pulmonary venous hypertension, determining type of PH, and choosing initial therapy. WHO indicates World Health Organization. aBased on the results of initial testing, consider further evaluation with high-resolution chest computed tomography (CT), CT angiography, or transesophageal echocardiography when indicated.
Sample echocardiographic imaging from the case patient. A, Global right ventricular (RV) systolic function can be assessed by RV fractional area change (reference value, >0.35). B, Longitudinal RV systolic function can be assessed by tricuspid annular plane systolic excursion (normal, >1.6 cm) and tissue Doppler peak systolic velocity of the basal RV free wall (reference value, >10 cm/s). These echocardiographic images were obtained 6 months after treatment and demonstrate near-normalization of RV systolic function in the case patient. Data for reference values are obtained from Rudski et al.31 See of the case patient's baseline echocardiogram and the echocardiographic findings of 2 additional patients for comparison.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
Transthoracic Echocardiograms of 3 Patients With Pulmonary Hypertension
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Patients Referred for Echocardiograms
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.